+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Atrial Fibrillation - Pipeline Insight, 2021

  • ID: 4989105
  • Drug Pipelines
  • February 2021
  • Region: Global
  • 60 pages
  • DelveInsight
1 of 3

FEATURED COMPANIES

  • Acesion Pharma
  • Merz Pharma
  • Milestone Pharmaceuticals
  • Novartis
  • OMEICOS Therapeutics
  • MORE
This “Atrial Fibrillation - Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Atrial Fibrillation pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
Atrial Fibrillation Understanding

Atrial Fibrillation: Overview

Atrial fibrillation refers to the most common type of abnormal heart rhythm. It is an irregular and often rapid heart rate that can increase your risk of strokes, heart failure and other heart-related complications. During this condition, the heart's two upper chambers (the atria) beat chaotically and irregularly - out of coordination with the two lower chambers (the ventricles) of the heart. Atrial fibrillation symptoms often include heart palpitations, shortness of breath and weakness. A major concern related to atrial fibrillation is the development of blood clots within the upper chambers of the heart. The blood clots formed in the heart may circulate to other organs and result in blocked blood flow (ischemia).

"Atrial fibrillation - Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Atrial fibrillation pipeline landscape is provided which includes the disease overview and Atrial fibrillation treatment guidelines. The assessment part of the report embraces, in depth Atrial fibrillation commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Atrial fibrillation collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
  • The companies and academics are working to assess challenges and seek opportunities that could influence Atrial Fibrillation R&D. The therapies under development are focused on novel approaches to treat/improve Atrial Fibrillation.
Atrial Fibrillation Emerging Drugs Chapters

This segment of the Atrial Fibrillation report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Atrial Fibrillation Emerging Drugs
  • Etripamil: Milestone Pharmaceuticals
Etripamil, the Company's lead investigational product, is designed to be a rapid-response therapy for episodic cardiovascular conditions. The novel calcium channel blocker is self-administered via a nasal spray, which may shift the current treatment paradigm for many patients with PSVT from the emergency department to the at-home setting. Milestone is conducting a comprehensive development program for etripamil, with Phase 3 trials underway in PSVT, and plans to commence a Phase 2 proof-of-concept trial in patients with atrial fibrillation with rapid ventricular rate, with subsequent studies expected in other conditions where calcium channel blockers are used.
  • OMT 28: OMEICOS Therapeutics
OMT-28 is a stable synthetic small molecule analog of the natural omega-3 fatty acid metabolite 17, 18-EEQ, which has a structure optimized to provide efficacy, safety, and oral availability. The compound has proven its anti-arrhythmic, cardioprotective, and anti-fibrotic potential in different in vivo models. Currently, it is in phase 2 of clinical trials for the treatment of atrial fibrillation.
  • HBI-3000 (sulcardine sulfate trihydrate) : HUYA Bioscience International
HBI-3000 (sulcardine sulfate trihydrate; Bai, et al. 2012) is a multi-ion channel blocker with effects on INa-Peak, INa-Late, ICa,L, and IKr with similar in vitro potencies across these various ion channels in human atrial cardiomyocytes. It is being developed by HUYA Bioscience International® (HUYABIO™) for the conversion of recent onset atrial fibrillation (AF). Currently undergoing phase 1 of clinical trials.
  • AP 30663: Acesion Pharma
It is based on inhibition of SK channels - ion channels present in the atria that play a role in regulating the cardiac rhythm. Blocking these ion channels with a functionally atrial selective drug helps avoid deleterious effects on the ventricles. Targeting the SK channels thereby constitutes a novel and promising approach for an effective treatment for AF with an expected higher safety and tolerability profile.

Atrial Fibrillation: Therapeutic Assessment

This segment of the report provides insights about the different Atrial Fibrillation drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Atrial Fibrillation

There are approx. 5+ key companies which are developing the therapies for Atrial Fibrillation. The companies which have their Atrial Fibrillation drug candidates in the mid to advanced stage, i.e. Phase II include, Acesion Pharma and others.

The report covers around 5+ products under different phases of clinical development like
  • Late-stage products (Phase III)
  • Mid-stage products (Phase II and Phase I/II)
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
Route of Administration

Atrial Fibrillation pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Subcutaneous
  • Intravenous
  • Oral
  • Intramuscular
  • Molecule Type
Products have been categorized under various Molecule types such as
  • Small molecules
  • Natural metabolites
  • Monoclonal antibodies
  • Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Atrial Fibrillation: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Atrial Fibrillation therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Atrial Fibrillation drugs.

Atrial Fibrillation Report Insights
  • Atrial Fibrillation Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
Atrial Fibrillation Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions Answered

Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Atrial Fibrillation drugs?
  • How many Atrial Fibrillation drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Atrial Fibrillation?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Atrial Fibrillation therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Atrial Fibrillation and their status?
  • What are the key designations that have been granted to the emerging drugs?
Key Players
  • Milestone Pharmaceuticals
  • OMEICOS Therapeutics
  • Novartis
  • HUYA Bioscience International
  • Acesion Pharma
  • Merz Pharma
Key Products
  • Etripamil
  • OMT28
  • HSY244
  • HBI-3000
  • AP 30663
  • Botulinum toxin A


This report will be delivered within 2 business days.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Acesion Pharma
  • Merz Pharma
  • Milestone Pharmaceuticals
  • Novartis
  • OMEICOS Therapeutics
  • MORE
Introduction

Executive Summary

Atrial Fibrillation: Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management
Pipeline Therapeutics
  • Comparative Analysis
Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type
Atrial Fibrillation - Analytical Perspective

In-depth Commercial Assessment
  • Atrial Fibrillation companies' collaborations, Licensing, Acquisition - Deal Value Trends
Atrial Fibrillation Collaboration Deals
  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
  • Comparative Analysis
Botulinum toxin A: Merz Pharma
  • Product Description
  • Research and Development
  • Product Development Activities
Mid Stage Products (Phase II)
  • Comparative Analysis
AP 30663: Acesion Pharma
  • Product Description
  • Research and Development
  • Product Development Activities
Early-Stage Products (Phase I)
  • Comparative Analysis
HBI-3000: HUYA Bioscience International
  • Product Description
  • Research and Development
  • Product Development Activities
Inactive Products
  • Comparative Analysis
Atrial Fibrillation Key Companies

Atrial Fibrillation Key Products

Atrial Fibrillation - Unmet Needs

Atrial Fibrillation - Market Drivers and Barriers

Atrial Fibrillation - Future Perspectives and Conclusion

Atrial Fibrillation Analyst Views

Atrial Fibrillation Key Companies

Appendix

List of Tables
Table 1 Total Products for Atrial Fibrillation
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List of Figures
Figure 1 Total Products for Atrial Fibrillation
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Note: Product cover images may vary from those shown
3 of 3
  • Milestone Pharmaceuticals
  • OMEICOS Therapeutics
  • Novartis
  • HUYA Bioscience International
  • Acesion Pharma
  • Merz Pharma
Note: Product cover images may vary from those shown
Adroll
adroll